Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

Relapsed/Refractory Non-Hodgkin Lymphoma

Bristol-Myers Squibb308 participantsStarted Dec 2023

Phoenix, Arizona, United States • Duarte, California, United States • Jacksonville, Florida, United States +62 more locations

RECRUITINGPhase 1/2

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

NCT05880043

This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma.

Advanced Solid TumorsRelapsed/Refractory Non-Hodgkin LymphomaRelapsed/Refractory Multiple Myeloma

GI Cell, Inc.50 participantsStarted Apr 2023

Seoul, South Korea • Seoul, South Korea • Seoul, South Korea +1 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies